Clinical Trial

Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
Cholecystokinin-2 (CCK2) receptor is overexpressed in more than 90% of MTC cases, and preclinical studies have shown that 68Ga-MGS5 (targeting CCK2) has good stability in vivo and is promising for diagnosis and staging of MTC. This prospective study will compare the diagnostic effects of 68Ga-MGS5 and 68Ga-DOTATATE on MTC primary foci, lymph node metastasis, and distant metastasis, and explore the effect of 68Ga-MGS5 PET/CT on the clinical staging (TNM staging) of MTC.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06520319
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Medullary Thyroid Carcinoma
Enrollment 20 participants
Start Date 2023-06-21
Primary Completion 2024-12 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2024-07-25